Affimed (NASDAQ:AFMD) Stock Rating Lowered by BidaskClub

Share on StockTwits

BidaskClub cut shares of Affimed (NASDAQ:AFMD) from a sell rating to a strong sell rating in a research note published on Tuesday, September 18th.

A number of other research firms have also recently issued reports on AFMD. ValuEngine cut shares of Affimed from a strong-buy rating to a buy rating in a research note on Thursday, September 13th. Jefferies Financial Group upgraded shares of Affimed from a hold rating to a buy rating and boosted their price objective for the stock from $1.80 to $4.00 in a research report on Tuesday, August 28th. BMO Capital Markets boosted their price objective on shares of Affimed from $4.00 to $5.00 and gave the stock an outperform rating in a research report on Tuesday, August 28th. Finally, Zacks Investment Research raised shares of Affimed from a sell rating to a hold rating in a report on Tuesday, June 19th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company. The company presently has an average rating of Hold and a consensus target price of $4.81.

AFMD stock traded up $0.07 during trading on Tuesday, reaching $3.38. 583,792 shares of the stock were exchanged, compared to its average volume of 1,101,211. Affimed has a twelve month low of $1.15 and a twelve month high of $7.35. The company has a market cap of $271.40 million, a PE ratio of -4.33 and a beta of 3.57. The company has a quick ratio of 5.33, a current ratio of 5.36 and a debt-to-equity ratio of 0.06.

Affimed (NASDAQ:AFMD) last released its earnings results on Wednesday, August 8th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.01. The business had revenue of $0.18 million for the quarter, compared to the consensus estimate of $0.61 million. Affimed had a negative return on equity of 74.04% and a negative net margin of 1,723.04%. On average, equities research analysts anticipate that Affimed will post -0.63 EPS for the current year.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Renaissance Technologies LLC lifted its position in Affimed by 38.8% in the 2nd quarter. Renaissance Technologies LLC now owns 177,510 shares of the biopharmaceutical company’s stock valued at $293,000 after acquiring an additional 49,610 shares in the last quarter. Stanley Laman Group Ltd. bought a new stake in Affimed during the 2nd quarter worth about $100,000. Canada Pension Plan Investment Board bought a new stake in Affimed during the 2nd quarter worth about $165,000. Iguana Healthcare Management LLC bought a new stake in Affimed during the 1st quarter worth about $555,000. Finally, Millennium Management LLC bought a new stake in Affimed during the 1st quarter worth about $4,731,000. 40.63% of the stock is currently owned by institutional investors and hedge funds.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead candidate is AFM13, a natural killer cell (NK-cell) TandAb, which is in Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma.

See Also: How does inflation affect different investments?

Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.